Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?

Background: Amphotericin B is efficacious for the treatment of systemic candidiasis, however it has potentially serious toxic effects. Administration as lipid emulsions has been advocated to decrease its toxicity. Aim: To compare the safety and tolerance of amphotericin B administered as lipid emuls...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hernández P,Glenn, Altermatt C,Fernando, Bernucci P,Francisca, Acuña C,Darwin, Apablaza E,Felipe, Valenzuela P,Felipe, Lefio C,Alvaro, Pérez C,Carlos, Bugedo T,Guillermo, Castillo F,Luis
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2000
Materias:	Adverse effects Amphotericin B Antibiotics, antifungal Drug toxicity
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001000004
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872000001000004
record_format	dspace
spelling	oai:scielo:S0034-988720000010000042001-01-29Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?Hernández P,GlennAltermatt C,FernandoBernucci P,FranciscaAcuña C,DarwinApablaza E,FelipeValenzuela P,FelipeLefio C,AlvaroPérez C,CarlosBugedo T,GuillermoCastillo F,Luis Adverse effects Amphotericin B Antibiotics, antifungal Drug toxicity Background: Amphotericin B is efficacious for the treatment of systemic candidiasis, however it has potentially serious toxic effects. Administration as lipid emulsions has been advocated to decrease its toxicity. Aim: To compare the safety and tolerance of amphotericin B administered as lipid emulsion or dissolved in dextrose in water. Patients and methods: Forty five patients with confirmed or highly suspected systemic candidiasis were studied. Between January 1996 and June 1997 amphotericin B was administered in dextrose in water to 17 patients (group 1). Between July 1997 and December 1998, the drug was delivered in lipid emulsions (Intralipid, group 2). Clinical and laboratory parameters (serum creatinine, urea nitrogen and potassium), were assessed daily. Results: Both treatment groups were clinically comparable and had the same survival. Accumulative amphotericin B dose administered was 343.2 ± 197 and 414.6 ± 518 mg respectively. Hypokalemia was more frequent in group 2 (52 and 25 % respectively, p < 0.05). There were no differences in the outcome of renal function or other adverse reactions. Conclusions: Administration of amphotericin B as lipid emulsions did not reduce its toxicity in critical patients (Rev Méd Chile 2000; 128: 1101-07)info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.128 n.10 20002000-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001000004es10.4067/S0034-98872000001000004
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Adverse effects Amphotericin B Antibiotics, antifungal Drug toxicity
spellingShingle	Adverse effects Amphotericin B Antibiotics, antifungal Drug toxicity Hernández P,Glenn Altermatt C,Fernando Bernucci P,Francisca Acuña C,Darwin Apablaza E,Felipe Valenzuela P,Felipe Lefio C,Alvaro Pérez C,Carlos Bugedo T,Guillermo Castillo F,Luis Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
description	Background: Amphotericin B is efficacious for the treatment of systemic candidiasis, however it has potentially serious toxic effects. Administration as lipid emulsions has been advocated to decrease its toxicity. Aim: To compare the safety and tolerance of amphotericin B administered as lipid emulsion or dissolved in dextrose in water. Patients and methods: Forty five patients with confirmed or highly suspected systemic candidiasis were studied. Between January 1996 and June 1997 amphotericin B was administered in dextrose in water to 17 patients (group 1). Between July 1997 and December 1998, the drug was delivered in lipid emulsions (Intralipid, group 2). Clinical and laboratory parameters (serum creatinine, urea nitrogen and potassium), were assessed daily. Results: Both treatment groups were clinically comparable and had the same survival. Accumulative amphotericin B dose administered was 343.2 ± 197 and 414.6 ± 518 mg respectively. Hypokalemia was more frequent in group 2 (52 and 25 % respectively, p < 0.05). There were no differences in the outcome of renal function or other adverse reactions. Conclusions: Administration of amphotericin B as lipid emulsions did not reduce its toxicity in critical patients (Rev Méd Chile 2000; 128: 1101-07)
author	Hernández P,Glenn Altermatt C,Fernando Bernucci P,Francisca Acuña C,Darwin Apablaza E,Felipe Valenzuela P,Felipe Lefio C,Alvaro Pérez C,Carlos Bugedo T,Guillermo Castillo F,Luis
author_facet	Hernández P,Glenn Altermatt C,Fernando Bernucci P,Francisca Acuña C,Darwin Apablaza E,Felipe Valenzuela P,Felipe Lefio C,Alvaro Pérez C,Carlos Bugedo T,Guillermo Castillo F,Luis
author_sort	Hernández P,Glenn
title	Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
title_short	Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
title_full	Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
title_fullStr	Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
title_full_unstemmed	Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
title_sort	uso de anfotericina b en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?
publisher	Sociedad Médica de Santiago
publishDate	2000
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872000001000004
work_keys_str_mv	AT hernandezpglenn usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT altermattcfernando usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT bernuccipfrancisca usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT acunacdarwin usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT apablazaefelipe usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT valenzuelapfelipe usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT lefiocalvaro usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT perezccarlos usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT bugedotguillermo usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos AT castillofluis usodeanfotericinabenmezclalipidicaprevienelatoxicidaddeladrogaenpacientescriticos
_version_	1718435939647225856

Uso de anfotericina B en mezcla lipídica: ¿previene la toxicidad de la droga en pacientes críticos?

Ejemplares similares